Connect with us
European Gaming Congress 2024

Artificial Intelligence

Neuroendocrine Tumor Treatment Global Market Report 2023: Developments and Approval of Novel Drugs to Boost Growth

Published

on

<!– Name:DistributionId Value:8796929 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2790 –> <!– Name:CustomerId Value:1026737 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:7b39603b-7023-473b-a4fb-3900664ded03 –>

Dublin, March 28, 2023 (GLOBE NEWSWIRE) — The “Neuroendocrine Tumor Treatment Market – Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition” report has been added to ResearchAndMarkets.com’s offering.

The global neuroendocrine tumor treatment market is anticipated to escalate in the forecast period, 2024-2028. This can be attributed to the rising prevalence of neuroendocrine tumors across the globe.

The incidence of neuroendocrine tumors has increased notably in the past three to four decades, according to an article published in the Journal of Cancers in April 2022. Neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC) disease, multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), and Von Hippel-Lindau syndrome (VHL) can be owed to the increased prevalence of neuroendocrine tumor (NET). In the United States, more than 12,000 people are diagnosed with a neuroendocrine tumor per year, and around 175,000 people are living with it, according to the most recent American Society of Clinical Oncology Neuroendocrine Tumor Statistics, which was updated in February 2022.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences – Genetic and Rare Diseases Information Center. The high frequency of neuroendocrine cancer patients worldwide is anticipated to contribute to the market’s growth.

Advertisement
Stake.com

The treatment techniques for neuroendocrine tumors such as targeted therapy, radionuclide treatment, somatostatin analogs, immunotherapy, CAR-T-Cell therapy, INF ?, trans arterial treatment, vaccines, bispecific antibodies, and cytotoxic chemotherapy of highly differentiated and low differentiated G1 and G2 GEP neuroendocrine tumor treatments (NETs) have also observed innovations in the past few years. This advancement in treatment techniques has led to a robust improvement in the growth of the neuroendocrine tumor treatment market. Furthermore, there has been a severe betterment in the survival rates of all neuroendocrine tumor treatments, according to a study published in the JAMA Oncology Journal in 2017.

Increased Government Initiatives

The governments of many developed nations like the United States are raising funds for research in cancer to assist in its diagnosis as well as treatment. The government is also funding numerous clinical trials to encourage companies to develop successful and effective cancer treatments. For instance, with federal government funding in cancer research, which is essential to assuring a future free of cancer, the American Institute for Cancer Research has financed almost USD110 million in research as of April 2021.

Additionally, under the 2021 Rare Cancers, Rare Illnesses and Unmet Need (RCRDUN) grant opportunity, The Department of Health of the Commonwealth of Australia January 2022 announced the availability of a grant for the study of rare cancers and rare diseases for USD 63.4 million.

Moreover, for the project `Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumor: the AUS-NET Trial,` Flinders University specifically obtained USD 2,374,220.10 in funding. Also, USD 1.5 million was invested by The Neuroendocrine Tumor Research Foundation (NETRF) for the development of Peptide Receptor Radionuclide Therapy (PRRT), an advanced radiation therapy.

Advertisement
Stake.com

Steps were taken by the Companies

Plenty of players in the industry are also adopting strategies, for example, partnerships and collaborations, novel product launches, agreements related to distribution along with a regional extension to establish their market position. For example, Boehringer Ingelheim GmbH declared an investment of USD 270 million for the construction of a new Biologicals Development Center (BDC) that will be specializing in immunology as well as immune-oncology in June 2018. Additionally, Novartis AG, in January 2018 announced to buy of all the ordinary shares from its subsidiary group Novartis Groupe France S.A., also inclusive of Advanced Accelerator Applications S.A. (AAA).

Market Dynamics

Drivers

  • Developments and Approval of Novel Drugs
  • Use of Artificial Intelligence (AI) in Treatment Techniques
  • Increased Government and Company’s’ Initiatives

Challenges

  • High Cost of the Treatment
  • Associated Side Effects of the Treatment
  • Stringent Regulatory Framework

Market Trends & Developments

  • Upcoming Patient Assistance Programs (PAPs)
  • Ongoing Clinical Trials and R&D Programs
  • Adoption of Next-Generation Sequencing Techniques

Report Scope:

In this report, global neuroendocrine tumor market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advertisement
Stake.com

Neuroendocrine Tumor Treatments Market, By Product Analysis:

  • Somatostatin Analogs (SSA)
  • Targeted Therapy
  • Others

Neuroendocrine Tumor Treatments Market, By Site Analysis:

  • Lungs
  • Pancreas
  • Colon
  • Small Intestine
  • Others

Neuroendocrine Tumor Treatments Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Neuroendocrine Tumor Treatments Market, By Region:

  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • North America
  • United States
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

Advertisement
Stake.com

5. Clinical Trial Analysis

6. Global Neuroendocrine Tumor Treatment Market Outlook

7. Asia-Pacific Neuroendocrine Tumor Treatment Market Outlook

8. Europe Neuroendocrine Tumor Treatment Market Outlook

9. North America Neuroendocrine Tumor Treatment Market Outlook

Advertisement
Stake.com

10. South America Neuroendocrine Tumor Treatment Market Outlook

11. Middle East and Africa Neuroendocrine Tumor Treatment Market Outlook

12. Market Dynamics

13. Market Trends & Developments

14. Competitive Landscape

Advertisement
Stake.com

15. Strategic Recommendations

A selection of companies mentioned in this report includes

  • F Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co
  • Eli Lilly & Co
  • Novartis AG
  • Pfizer Inc
  • Amgen Inc
  • Exelixis Inc
  • Teva Pharmaceutical Industries Ltd
  • AVEO Pharmaceuticals Inc
  • Hutchison MediPharma Ltd

For more information about this report visit https://www.researchandmarkets.com/r/khgspl

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Medasense Announces a Strategic Agreement With Global Medical Company, Nihon Kohden Corporation

Published

on

medasense-announces-a-strategic-agreement-with-global-medical-company,-nihon-kohden-corporation

RAMAT GAN, Israel, June 26, 2024 /PRNewswire/ — Medasense, a global leader in pain monitoring solutions, is proud to announce a strategic partnership with Nihon Kohden for the exclusive distribution of its revolutionary pain monitoring device in Japan. This partnership is intended to transform pain management practices across Japanese healthcare facilities, offering a significant advancement in patient care.

 
Nihon Kohden, renowned for its history of excellence in providing innovative high quality, reliable medical technology that improves the way healthcare is practiced, is partnering with Medasense to introduce its nociception monitor to the Japanese market. This cutting-edge device, with its state-of-the-art AI powered NOL – Nociception Level Index®, provides real-time, objective pain monitoring, enabling the personalization and optimization of pain treatment. It will be accessible to hospitals and clinics throughout Japan through Nihon Kohden’s extensive distribution channels pending regulatory approval.
Medasense’s CEO & Founder, Galit Zuckerman, expressed enthusiasm about the collaboration: “We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions. Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden’s established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor.”
NOL monitoring provides an AI powered, clinically validated index to objectively quantify the physiological response to pain (nociception) supporting clinicians in delivering personalized anesthesia tailored to patient requirements. With over 40 peer reviewed publications, clinical studies have demonstrated that NOL-guided analgesia resulted in intraoperative opioid sparing, and improved post operative pain scores and patient recovery.1,2
For more information about Medasense and Nihon Kohden, please visit www.medasense.com and www.nihonkohden.com/.
About Medasense and NOL – Nociception Level Index® Technology
Medasense is transforming pain management with its breakthrough technology that empowers clinicians to optimize and personalize pain control, significantly reducing the risk of pain or of overmedication. The company’s flagship product, the PMD-200™, equipped with the NOL-Nociception Level Index®, leverages advanced artificial intelligence and a proprietary non-invasive sensor system. This unique platform provides objective monitoring and quantification of a patient’s pain response, making it an essential tool in an operating room and critical care unit settings where patients cannot communicate their pain levels. The PMD-200 is the first and only monitor to be authorized by the FDA for pain measurement for anaesthesiology. It has been used in over 100,000 surgeries worldwide, and is commercially available in the US, Europe, Canada, Latin America and Israel.
Watch Medasense’s 1-minute video
About Nihon Kohden
Founded in 1951, Nihon Kohden is a global leader of medical solutions with the goal to improve healthcare with advanced technology. For more than 70 years, Nihon Kohden has continued to provide a wide range of medical electronic equipment including EEG, EMG/EP measuring systems, electrocardiographs, bedside monitors, defibrillators, AEDs, ventilators, and hematology instruments.
Nihon Kohden utilizes cutting-edge technology to support medical treatment in all clinical areas, integrating medical devices into the IT network to meet customers’ requirements and offers a wide, comprehensive solution.
For further information please contact:Rachel Weissbrod, VP Clinical & Market Development, [email protected] 
1.  Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. British Journal of Anaesthesia, In Press. DOI:https://doi.org/10.1016/j.bja.2020.07.057
2.  Fleur S. Meijer, Chris H. Martini, Suzanne Broens, Martijn Boon, Marieke Niesters, Leon Aarts, Erik Olofsen, Monique van Velzen, Albert Dahan. Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology (2019); 130:745–755
Logo: https://mma.prnewswire.com/media/1169999/Medasense_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/medasense-announces-a-strategic-agreement-with-global-medical-company-nihon-kohden-corporation-302183281.html

Continue Reading

Artificial Intelligence

IoT Sensors Market Set to Surpass USD 107.74 Billion by 2031| SkyQuest Technology

Published

on

iot-sensors-market-set-to-surpass-usd-107.74-billion-by-2031|-skyquest-technology

WESTFORD, Mass., June 26, 2024 /PRNewswire/ — According to SkyQuest, the global IoT Sensors Market size was valued at USD 11.20 Billion in 2022 and is poised to grow from USD 14.40 Billion in 2023 to USD 107.74 Billion by 2031, at a CAGR of 28.60% during the forecast period (2024-2031).

IoT sensors are sensors that are specifically designed for Internet of Things (IoT) devices and applications. High adoption of IoT devices and growing advancements in IoT technologies are fostering demand for novel IoT sensors. The global IoT sensors market is segmented into sensor type, vertical, and region.
Download a detailed overview:
https://www.skyquestt.com/sample-request/iot-sensors-market
IoT Sensors Market Overview: 
Report Coverage 
Details 
Market Revenue in 2023 
$ 14.40 billion 
Estimated Value by 2031 
$ 107.74 billion 
Growth Rate 
Poised to grow at a CAGR of 28.60% 
Forecast Period 
2024–2031 
Forecast Units 
Value (USD Billion) 
Report Coverage 
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends 
Segments Covered 
Sensor Type, Network Technology, and Vertical
Geographies Covered 
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Report Highlights 
Updated financial information / product portfolio of players 
Key Market Opportunities 
Proliferation of Smart Devices
Key Market Drivers 
Advancements in Wireless Communication Technologies
Segments covered in IoT Sensors Market are as follows:
Sensor TypeTemperature Sensor, Pressure Sensor, Humidity Sensor, Flow Sensor, Accelerometer, Magnetometer, Gyroscope, Inertial Sensor, Image Sensor, Touch Sensor, Proximity Sensor, Acoustic Sensor, Motion Sensor, Occupancy Sensor (Image Processing Occupancy Sensors, Intelligent Occupancy Sensors), CO2 Sensor, Other Sensors (Light sensor, Radar sensor)Network TechnologyWired (KNX, LonWorks, Ethernet, MODBUS, DALI), Wireless (Wi-Fi [Bluetooth Smart, Wi-Fi Bluetooth Smart, Bluetooth Smart / Ant+, Bluetooth 5]), ZIGBEE, Z-WAVE, NFC, RFID, ENOCEAN, THREAD, GLoWPAN, WIRELESS-HART, Frocess field bus, DECT-ULE, Others (ANT+, ISA100, GPS, Sub-Gig, and Cellular)VerticalConsumer (Home automation, Smart cities, Wearable electronics), Commercial (Retail, Aerospace and Defense, Logistics and supply chain, Entertainment, Financial Institutes, Corporate Offices), Industrial (Energy, Industrial Automation, Transportation, Healthcare, Smart agriculture)Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/iot-sensors-market
Pressure Sensors Keeping Up the Pressure in IoT Sensors Market
Pressure sensors are used in cars as well as industrial facilities used to make cars and are a vital part of almost all kinds of technical devices or products. Pressure sensors play a vital role in maintaining the safety of multiple operations by keeping the pressure in check and warning users when it reaches unsafe levels. High emphasis on security around the world is projected to promote the demand for pressure sensors in the future. Aerospace, healthcare, and manufacturing are some key industry verticals where demand for pressure sensors will always be high.
The rapid surge in the use of gesture-sensitive devices all over the world is promoting the demand for accelerometer sensors. From factory automation to smart homes, the use of accelerometer sensors is projected to soar high over the coming years. Rising sales of fitness trackers and gaming consoles are also estimated to bolster the demand for accelerometer sensors in the future.
Temperature sensors are also anticipated to be highly popular in multiple IoT devices owing to the surging demand for temperature monitoring and control in various applications. Temperature sensors are also highly vital in maintaining the safety of IoT devices and surroundings to avoid mishaps due to excessive increases or drops in temperatures. Other types of sensors include motion sensors, light sensors, CO2 sensors, occupancy sensors, gyroscopes, proximity sensors, etc. All these different types of sensors are highly crucial for sustained IoT sensors market growth across the forecast period and beyond, therefore investing in any of these could help market players bolster their share.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/iot-sensors-market
High IoT Adoption Allows Industrial Vertical to Take Crown in Revenue Generation
The use of IoT technologies in the industrial vertical is increasing rapidly, which is why this sub-segment holds prominence in the global IoT sensors market. High demand for automation and increasing use of IoT devices to achieve the same are slated to foster new opportunities for IoT sensors market players in this segment. High adoption of the Industry 4.0 trend is also helping this sub-segment boost the demand for IoT sensors. Development of smart infrastructure is also boosting the demand for IoT sensors in the commercial vertical. From healthcare to construction, multiple industry verticals are promoting the use of IoT technologies and thereby driving sales of IoT sensors as well.
Pressure sensors for IoT devices and IoT sensors for industrial verticals are projected to be highly popular. IoT sensor companies should invest in these sub-segments to get the best return on their investments. Meanwhile, new companies can experiment with other segments to find what suits the best for their business and focus on the same. As per analysts, investing in the development of novel proximity and accelerometer sensors will be highly rewarding for upcoming IoT sensor companies.
Related Reports:
Sensor Market
Internet Of Things (IoT) Market
Internet Of Things (IoT) Professional Services Market
IoT Security Market
5G IoT Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific. 
Contact:Mr. Jagraj SinghSkyQuest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/
Logo: https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg 
 

View original content:https://www.prnewswire.co.uk/news-releases/iot-sensors-market-set-to-surpass-usd-107-74-billion-by-2031-skyquest-technology-302183053.html

Continue Reading

Artificial Intelligence

Actian Recognized as Exemplary Vendor in Ventana Research Data Platform Buyers’ Guide

Published

on

actian-recognized-as-exemplary-vendor-in-ventana-research-data-platform-buyers’-guide

Strength in Manageability and Customer Experience Earn Actian High Regard in Ventana Research Report
ROUND ROCK, Texas, June 26, 2024 /PRNewswire/ — Actian, the data and analytics division of HCLSoftware, today announced it was named an Exemplary vendor and Overall Leader in Manageability in Ventana Research’s 2024 Data Platform Buyers’ Guide for the Actian Data Platform. Ventana’s extensive approach to the Buyers’ Guide evaluates Operational and Analytic Data Platform vendors in seven key categories that are weighted to reflect product and customer experience.

“The launch of Actian Data Platform was a significant step forward for Actian that combined its capabilities for data integration, with the company’s operational databases and analytic databases,” said Matt Aslett, director of research at Ventana Research, now part of ISG. “Providing a single environment that can manage data across multiple clouds as well as on-premises contributed to Actian being classified as Exemplary and a Leader in Manageability in Ventana Research’s Buyers Guides for Analytic Data Platforms, Operational Data Platforms and Overall Data Platforms.”
For Operational and Analytic Data Platforms, Actian was ranked highly for customer experience alongside vendors such as Google Cloud and Salesforce. Customers praised Actian’s strong product roadmap, use cases, and references available on its website, which provide valuable insights to prospective buyers. In addition, Actian was designated as a Leader in Manageability due to its strong license, use, and audit capabilities.
“Being recognized as an Exemplary vendor and a leader in Manageability is a testament to our commitment to delivering user-friendly and robust data management solutions,” said Jennifer Jackson, Chief Marketing Officer at Actian. “We are dedicated to supporting our customers throughout their entire journey with our products, ensuring they have the tools and support they need to succeed. This recognition by Ventana Research validates our efforts and motivates us to continue enhancing our platform to meet and exceed customer expectations.”
To learn more about Actian’s designation in the report please read this blog post and download the report here. 
About ActianActian makes data easy. We deliver cloud, hybrid, and on-premises data solutions that simplify how people connect, manage and analyze data. We transform business by enabling customers to make confident, data-driven decisions that accelerate their organization’s growth. Our data platform integrates seamlessly, performs reliably, and delivers industry-leading speeds at an affordable cost. Actian is a division of HCLSoftware.
Media Contacts
Danielle LeeSenior Director – Global Analyst Relations & Public [email protected] 
Ali WheelerPublic Relations [email protected] 
Logo – https://mma.prnewswire.com/media/2429927/Actian_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/actian-recognized-as-exemplary-vendor-in-ventana-research-data-platform-buyers-guide-302182357.html

Continue Reading

Trending